Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease
Rheumatology International · 08.03.2024 · 44 (5) · 961-971
DOI: 10.1007/s00296-024-05551-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatology International, online erschienen am 08.03.2024. Verfasst von Hiroaki Harada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. haradamd@gm…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Dermatomyositis, Lung Diseases, Interstitial, Azetidines. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the prognosis of which is poor, and management is a major challenge. We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients. We reviewed 6 patients with anti-MDA5-DM-ILD who had been treated with tofacitinib at our institution. Five of the patients survived, although discontinuation of tofacitinib due to complications was frequently observed. In addition, a literature search of patients with anti-MDA5-DM-ILD who were treated with JAK inhibitors yielded 21 articles involving 79 cases. All patients except one were treated with tofacitinib, and the survival rate was 75.9%. Although not statistically confirmed, the deceased patients tended to be older and had higher ferritin levels. A total of 92 complications were observed, 11 of which resulted in JAK inhibitor discontinuation. Cytomegalovirus reactivation comprised a substantial percentage of all complications and of those patients who required JAK inhibitor discontinuation. Five cases with fatal infective complications were also observed. While tofacitinib has been proposed to be a therapeutic option for anti-MDA5-DM-ILD, other JAK inhibitors, including baricitinib, are a treatment option. Further investigation is warranted to optimize treatment of anti-MDA5-DM-ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. haradamd@gmail.com.
- Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
ORCID-Profile: Hiroaki Harada, Hirofumi Shoda, Haruka Tsuchiya, Makoto Misaki, Takayuki Sawada, Keishi Fujio
Zitieren
APA
Harada, H., Shoda, H., Tsuchiya, H., Misaki, M., Sawada, T., & Fujio, K. (2024). Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatology International, 44(5), 961-971. https://doi.org/10.1007/s00296-024-05551-2
Vancouver
Harada H, Shoda H, Tsuchiya H, Misaki M, Sawada T, Fujio K. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatology International. 2024;44(5):961-971. doi:10.1007/s00296-024-05551-2
BibTeX
@article{Harada2024,
author = {Harada, Hiroaki and Shoda, Hirofumi and Tsuchiya, Haruka and Misaki, Makoto and Sawada, Takayuki and Fujio, Keishi},
title = {Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease},
journal = {Rheumatology International},
year = {2024},
volume = {44},
number = {5},
pages = {961--971},
doi = {10.1007/s00296-024-05551-2}
}
EUVIMED